코오롱생명과학은 미국 식품의약국(FDA)이 자회사 코오롱티슈진이 개발 중인 인보사의 임상 3상 시험 보류를 해제하고 환자 투약을 재개토록 했다고 12일 밝혔다.
Kolon Life Sciences announced on the 12th that the US Food and Drug Administration (FDA) has lifted the suspension of the phase 3 clinical trial of Invossa, which is being developed by subsidiary Kolon TissueGene, and has allowed the resumption of patient medication.